Zhenyi Jin

Key Laboratory Of Regenerative Medicine
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

CD69 blockade restores the bone marrow niche and delays leukemogenesis in a mouse model of Nras G12D-driven chronic myelomonocytic leukemia.

CD69 blockade restores the bone marrow niche and delays leukemogenesis in a mouse model of Nras G12D-driven chronic myelomonocytic leukemia.

Journal: Cancer biology & therapy

Published: June 22, 2026

Heterogeneity of γδ T-cell subsets and their clinical correlation in patients with AML.

Heterogeneity of γδ T-cell subsets and their clinical correlation in patients with AML.

Journal: Frontiers in immunology

Published: December 27, 2024

Analysis of prognostic biomarker models of TXNIP/NLRP3/IL1B inflammasome pathway in patients with acute myeloid leukemia.

Analysis of prognostic biomarker models of TXNIP/NLRP3/IL1B inflammasome pathway in patients with acute myeloid leukemia.

Journal: International journal of medical sciences

Published: March 25, 2024

Higher TIGIT+ γδ TCM cells may predict poor prognosis in younger adult patients with non-acute promyelocytic AML.

Higher TIGIT+ γδ TCM cells may predict poor prognosis in younger adult patients with non-acute promyelocytic AML.

Journal: Frontiers in immunology

Published: October 13, 2023

Utilizing exosomes as sparking clinical biomarkers and therapeutic response in acute myeloid leukemia.

Utilizing exosomes as sparking clinical biomarkers and therapeutic response in acute myeloid leukemia.

Journal: Frontiers in immunology

Published: October 10, 2023

CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer.

CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer.

Journal: ImmunoTargets and therapy

Published: September 12, 2023

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.

Journal: Frontiers in immunology

Published: November 28, 2022

Increased PD-1+Foxp3+ γδ T cells associate with poor overall survival for patients with acute myeloid leukemia.

Increased PD-1+Foxp3+ γδ T cells associate with poor overall survival for patients with acute myeloid leukemia.

Journal: Frontiers in oncology

Published: October 17, 2022

TIGIT axis: novel immune checkpoints in anti-leukemia immunity.

TIGIT axis: novel immune checkpoints in anti-leukemia immunity.

Journal: Clinical and experimental medicine

Published: December 07, 2021

High TRGV 9 Subfamily Expression Marks an Improved Overall Survival in Patients With Acute Myeloid Leukemia.

High TRGV 9 Subfamily Expression Marks an Improved Overall Survival in Patients With Acute Myeloid Leukemia.

Journal: Frontiers in immunology

Published: November 27, 2021

Higher Expression of WT1 With Lower CD58 Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia.

Higher Expression of WT1 With Lower CD58 Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia.

Journal: Technology in cancer research & treatment

Published: November 05, 2021

Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT+ NK cells may be related to poor outcome in acute myeloid leukemia.

Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT+ NK cells may be related to poor outcome in acute myeloid leukemia.

Journal: Asia-Pacific journal of clinical oncology

Published: August 23, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026